Astellas Pharma Inc.
4503.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.68B
Close$
Share Statistics
| Market cap | $25.68 Billion |
|---|---|
| Enterprise Value | $368.57 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 15.76% |
|---|---|
| Return on Assets | 8.29% |
| Return on Invested Capital | 17.25% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.2 |
| Enterprise Value to EBIT | 0.88 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.59 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$52.62
Average shareholder expectationRevenue Estimate
$559.53 B
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$62.17
Average shareholder expectationRevenue Estimate
$582.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Astellas Pharma Inc.
14,099 employees
CEO: Kenji Yasukawa Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. ...